|
Dr. Ellison currently serves as Executive Vice President at Paramount BioSciences, LLC, a biotechnology and life sciences-focused company that promotes the development of promising in-licensed drug candidates. In that role, he is involved in the formation, guidance and support of Paramount’s pharmaceutical portfolio companies.
Prior to joining Paramount BioSciences, Dr. Ellison was Vice President of Clinical Development at Fibrogen, Inc, a privately held biotechnology-based company involved in the discovery, development and commercialization of novel therapeutics for fibrotic disorders, diabetic complications, anemia, ischemic disease, cancer and other areas of unmet medical need. Dr. Ellison has also served as the Vice President of Medical Affairs and Chief Medical Officer of Sanofi-Synthelabo, where he was responsible for several key oncology products including Eloxatin (oxaliplatin) for colorectal cancer and Eligard (leuprolide acetate for injectable suspension) for prostate cancer. He was Vice President, Medical Affairs and Chief Medical Officer of Hoffmann La Roche, Inc. from 1997 to 2002 and held several drug development positions with Roche Canada from 1990 to 1997.
Dr. Ellison holds an MD from the University of British Columbia and an MSc (with distinction) from The London School of Tropical Medicine and Hygiene.
| 